HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup
Archive

All News

Every briefing, headline, and filing we've published, newest first.

Regulation of AI in Prior Authorization and Claims Review: A Look at Federal and State Consumer Protections
PolicyKFF Health News ↗
Amid the growing use of artificial intelligence (AI) in the claims review cycle, this brief discusses the type…
May 6, 2026
SCOTUS temporarily restores online access to abortion pill after appeals court ruling
PolicyFiercePharma ↗
The U.S. Supreme Court has temporarily reinstated online access to the abortion pill mifepristone after a fede…
May 6, 2026
Madrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J
DealsFierceBiotech ↗
Madrigal Pharmaceuticals has struck a backloaded deal for the global license to an Arrowhead Pharmaceuticals p…
May 6, 2026
Cytokinetics’ Myqorzo Delivers Landmark Phase 3 Win in Non‑Obstructive HCM
PipelineBriefing
By succeeding in the ACACIA-HCM trial, Myqorzo could become the first approved treatment for non‑obstructive h…
May 6, 2026
MSD concludes Terns acquisition to expand CML pipeline
DealsPharmaceutical Technology ↗
MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic m…
May 6, 2026
STAT+: A new attack on AMA’s billing codes
PolicySTAT News ↗
A key GOP lawmaker is broadening the party's efforts to combat health care fraud.…
May 5, 2026
BioNTech to scale down manufacturing, over 1,800 jobs on the line
PeopleEndpoints News ↗
BioNTech is making big cuts to its manufacturing footprint. The German company said in its first-quarter earni…
May 5, 2026
What’s at stake in Amgen’s showdown with the FDA?
PolicyPharmaVoice ↗
The agency accused Amgen of manipulating data for its fast-growing drug Tavneos and wants it pulled from the m…
May 5, 2026
UCB inks $2B Candid buyout to join Gilead in autoimmune field
DealsFierceBiotech ↗
UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merge…
May 5, 2026
BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfolio
MoneyFiercePharma ↗
Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star hear…
May 5, 2026
CMS’s 2027 Medicare Advantage Rule Trades Transparency for Flexibility
PolicyBriefing
The final rule adds disclosure requirements for SSBCI benefits but eases prior consumer protection measures ar…
May 5, 2026
DataDrug Channels ↗
By Adam J. Fein, Ph.D.The Drug Channels Institute (DCI) team attended Asembia’s AXS26 Summit last week. Once a…
May 5, 2026
Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies
PolicySTAT News ↗
The Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a ruling that ha…
May 4, 2026
With $97M, Latus pursues a different kind of Huntington’s gene therapy
MoneyBioPharma Dive ↗
The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enab…
May 4, 2026
Protein degraders gain speed as Arvinas scores landmark approval
PipelinePharmaVoice ↗
Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrow…
May 4, 2026
FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype
PipelineFiercePharma ↗
The early FDA approval doesn't change Pfizer and Arvinas' plan to leave commercialization of the drug to a yet…
May 4, 2026
J&J axes $5B CAR-T dream months after touting best-in-disease efficacy
PipelineFierceBiotech ↗
Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliv…
May 4, 2026
Axsome Wins FDA Nod for Auvelity in Alzheimer’s Agitation
PipelineBriefing
Auvelity, already cleared for depression, becomes the first non-antipsychotic treatment for agitation in Alzhe…
May 4, 2026
UCB bets $2B on Candid's T cell engager ambitions
DealsEndpoints News ↗
Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in auto…
May 4, 2026
Summit's PD-1xVEGF interim trial miss surprises analysts, shares tumble
PipelineFiercePharma ↗
A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ s…
May 3, 2026
CBER chief Prasad steps aside, deputy takes the reins as search for successor continues
PeopleFierceBiotech ↗
Katherine Szarama, Ph.D., will take over as CBER director in an acting capacity while the search for a permane…
May 3, 2026
Seaport’s $255M Upsized IPO Defies the Big Pharma M&A Pull
MoneyBriefing
Seaport Therapeutics opted for a $255M Nasdaq IPO over an acquisition, underscoring renewed investor appetite …
May 3, 2026
Federal appeals court blocks mailing of abortion pill mifepristone
PolicySTAT News ↗
Mifepristone, involved in most abortions in the U.S., can now be distributed only in person and at clinics.…
May 2, 2026
Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
DealsFiercePharma ↗
Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema…
May 2, 2026
← Newer Page 22 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.